Cargando…
GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models
For many solid tumors, immune checkpoint blockade therapy has become first line treatment, yet a large proportion of patients with immunologically cold tumors do not benefit due to the paucity of tumor infiltrating lymphocytes. Here we show that the orphan G Protein-Coupled Receptor 182 (GPR182) con...
Autores principales: | Torphy, Robert J., Sun, Yi, Lin, Ronggui, Caffrey-Carr, Alayna, Fujiwara, Yuki, Ho, Felix, Miller, Emily N., McCarter, Martin D., Lyons, Traci R., Schulick, Richard D., Kedl, Ross M., Zhu, Yuwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748779/ https://www.ncbi.nlm.nih.gov/pubmed/35013216 http://dx.doi.org/10.1038/s41467-021-27658-x |
Ejemplares similares
-
The GPR171 pathway suppresses T cell activation and limits antitumor immunity
por: Fujiwara, Yuki, et al.
Publicado: (2021) -
GPR182 is a broadly scavenging atypical chemokine receptor influencing T-independent immunity
por: Melgrati, Serena, et al.
Publicado: (2023) -
Large chemokine binding spectrum of human and mouse atypical chemokine receptor GPR182 (ACKR5)
por: Bonnavion, Remy, et al.
Publicado: (2023) -
Immunotherapy for pancreatic cancer: Barriers and breakthroughs
por: Torphy, Robert J., et al.
Publicado: (2018) -
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
por: Torphy, Robert J., et al.
Publicado: (2017)